Dose dependent expression of FLT3 elicited minimal perturbation of p-BCR::ABL1 as well as p-STAT5, p-ERK, and p-AKT signaling, which are well-established downstream effectors of FLT3 in AML (Fig. 1G) [13]. The gene discussed is ABL1; the disease is acute myeloid leukemia.